Board of Directors

Elliott is a renowned scientific and industry leader who has been a member of the board of directors at Affinia for the past five years. He was a member of board of directors at the gene therapy pioneer Spark Therapeutics for five years. During that time, the company developed and launched Luxturna® (voretigene neparvovec-rzyl), the first AAV gene therapy in the United States, and was acquired by Roche for $4.3 billion. Elliott is a former executive vice president and director of Bristol Myers Squibb (BMS), where he also served as chief scientific officer and president of R&D. Under Elliott’s leadership at BMS, 14 new medicines were approved and Scrip Intelligence named him the best R&D chief in the pharmaceutical industry during his tenure. He currently serves as a member of the boards of directors at Alnylam Pharmaceuticals, Inc., Vir Biotechnology (VIR), and Tessera Therapeutics, and formerly served on the boards of directors of Adaptimmune Therapeutics (ADAP) and Surface Oncology (SURF). Elliott co-chairs Amgen’s Scientific Advisory Board and is a member of the Scientific Steering Committee for the Parker Institute for Cancer Immunotherapy. Elliott received a Ph.D., M.S., and B.S. in industrial engineering from Purdue University and an M.D. from the University of Chicago. He is board certified in internal medicine and pulmonary medicine and served on the faculty of the Department of Medicine, University of California, San Francisco from 1988-1992.